CompletedPhase 2NCT01762150
Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
Studying Collecting duct carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University Cancer Hospital & Institute
- Principal Investigator
- Jun Guo, MD,PHDPeking University Cancer Hospital & Institute
- Intervention
- Sorafenib(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2011 – 2018
Study locations (5)
- Beijing Cancer Hospital, Beijing, Beijing Municipality, China
- Sun Yat-sen university cancer center, Guangzhou, Guangdong, China
- Shenyang general hospital of Shenyang military command, Shenyang, Liaoning, China
- Xijing Hospital, Xi’an, Shanxi, China
- West China Hospital, Chengdu, Sichuan, China
Collaborators
Bayer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01762150 on ClinicalTrials.govOther trials for Collecting duct carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06302569Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary CarcinomaGiuseppe Procopio
- RECRUITINGPHASE2NCT06211114Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct CarcinomaPeking University Cancer Hospital & Institute